RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Cidara Therapeutics EBIT 2024

Cidara Therapeutics EBIT

-65.03 M USD

Cidara Therapeutics Dividend yield

Ticker

CDTX

ISIN

US1717571079

WKN

A14R2R

In 2024, Cidara Therapeutics's EBIT was -65.03 M USD, a 165.59% increase from the -24.48 M USD EBIT recorded in the previous year.

The Cidara Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e64.26
2027e-0.05
2026e-98.23
2025e-93.28
2024e-65.03
2023-24.48
2022-33.5
2021-42.26
2020-71.85
2019-41.72
2018-63.29
2017-55.72
2016-48.44
2015-32.31
2014-11.62
2013-1.08

Cidara Therapeutics Aktienanalyse

What does Cidara Therapeutics do?

Cidara Therapeutics Inc. is a biopharmaceutical company specializing in the development and marketing of innovative therapies for serious infectious diseases. The company was founded in 2013 and is headquartered in San Diego, California. The founders of Cidara Therapeutics Inc. aimed to develop a new class of antifungal drugs that are particularly effective against fungal infections. The underlying technology is based on the Cloudbreak® peptide platform, which allows for the production of drugs with improved efficacy and safety. The company also has research collaborations with leading scientists in the field of infectious diseases to advance the development of antibody therapy, vaccines, and other drugs. The business model of Cidara Therapeutics Inc. focuses on the development and marketing of innovative therapeutic products for unmet medical needs. The company has divided its products into three divisions: infectious diseases, oncology, and immunology. Cidara's product pipeline includes several innovative drugs that have shown efficacy in phase I and phase II clinical trials. The infectious diseases division initially focuses on the development of antifungal drugs for the treatment of Candida infections, which can be life-threatening for people with weakened immune systems. Cidara Therapeutics Inc. has already successfully completed a clinical trial for its lead product, rezafungin. Rezafungin is a long-acting, liposomal antifungal drug that enables a single dose for effective treatment of Candida infections. The oncology division focuses on the development of innovative immunotherapies that use the body's immune system to attack cancer cells. Cidara Therapeutics Inc. utilizes the Cloudbreak® platform technology to develop new drugs that specifically target certain types of cancer. The lead product in this pipeline is CD371, a monoclonal antibody targeting acute myeloid leukemia (AML). The immunology division focuses on developing therapeutics for autoimmune diseases that bring the body's immune system under medical control to reduce inflammation and damage to target organs. The lead product in this product line is Cloudbreak® immunomodulators, which specifically regulate immune responses and combat inflammation. Overall, Cidara Therapeutics Inc. is a promising company that focuses on the development and marketing of innovative drugs for high unmet medical needs. The company's diverse and well-balanced product pipelines in the areas of infectious diseases, oncology, and immunology demonstrate the great potential of this business model. With the advanced Cloudbreak® technology and the dedicated team, Cidara Therapeutics Inc. has the potential to take a global leadership role in drug development and save lives. Cidara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Cidara Therapeutics's EBIT

Cidara Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cidara Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cidara Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cidara Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cidara Therapeutics Stock

How much did Cidara Therapeutics achieve in EBIT for the current year?

In the current year, Cidara Therapeutics has achieved an EBIT of -65.03 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Cidara Therapeutics.

How has the EBIT of Cidara Therapeutics developed in recent years?

The EBIT of Cidara Therapeutics has increased by 165.592% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Cidara Therapeutics?

The EBIT of Cidara Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Cidara Therapeutics pay?

Over the past 12 months, Cidara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cidara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cidara Therapeutics?

The current dividend yield of Cidara Therapeutics is .

When does Cidara Therapeutics pay dividends?

Cidara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cidara Therapeutics?

Cidara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cidara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cidara Therapeutics located?

Cidara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cidara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cidara Therapeutics from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Cidara Therapeutics pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Cidara Therapeutics in the year 2023?

In the year 2023, Cidara Therapeutics distributed 0 USD as dividends.

In which currency does Cidara Therapeutics pay out the dividend?

The dividends of Cidara Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cidara Therapeutics

Our stock analysis for Cidara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cidara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.